Sana Biotechnology Inc vs Zoetis Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 36.6× Sana Biotechnology Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | ZTS | |
|---|---|---|
Market Cap | $873.84M | $31.95B |
Sector | Health | Health |
52-Week High | $5.92 | $156.76 |
52-Week Low | $2.68 | $71.91 |
Enterprise Value | $848.03M | $39.24B |
Dividend Yield | — | 2.78% |
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →